Vanessa Scanlon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vanessa Scanlon has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Archana Sanjay
Department of Orthopaedic Surgery, School of Medicine, UConn Health, 263 Farmington Avenue, Farmington, CT, 06030 USA
3 shared publications - Diane S. Krause
Department of Pathology, Yale School of Medicine, New Haven, Connecticut
3 shared publications Hicham Drissi
Department of Orthopaedic Surgery, United States; Department of Genetics and Genome Sciences, United States
2 shared publicationsNaga Suresh Adapala
Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT, United States of America
2 shared publicationsPing-Xia Zhang
Department of Laboratory Medicine
2 shared publications- Adam T. Hagymasi
University of Connecticut School, of Medicine
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 839
Acute FGF23 neutralization alters phosphate handling and bone marrow molecular responses in sickle cell disease mice
- 13 October 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 839
Open AccessAcute FGF23 neutralization alters phosphate handling and bone marrow molecular responses in sickle cell disease mice
- 9 April 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (10) , 2701-2717
Self-sustaining media-reconstituted GelMA bioink supports printable hematopoietic cultures
Tunable, bioprintable hydrogels are essential for mechanistic studies of hematopoietic stem and progenitor cell (HSPC) fate because stiffness, porosity, and dimension of culture are crucial for HSPC expansion and differentiation.
- 9 April 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (10) , 2701-2717
Self-sustaining media-reconstituted GelMA bioink supports printable hematopoietic cultures
Tunable, bioprintable hydrogels are essential for mechanistic studies of hematopoietic stem and progenitor cell (HSPC) fate because stiffness, porosity, and dimension of culture are crucial for HSPC expansion and differentiation.
- Open Access
- 17 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (12)
Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum
Aging is a primary risk factor for disease progression in multiple sclerosis (MS). Because of this, treatments that can reduce the consequences of molecular aging, like senescence, have been proposed as a strategy to address disease progression. However, the effects of senolytics, a class of drugs which selectively ablate senescent cells, on the central nervous system are largely unknown. Here, we examined the effects of senolytic treatment on myelination and oligodendrocyte function in vivo using C57BL6/J mice and in vitro using primary rat oligodendrocyte cultures. Initial data showed that naïve young (3 to 4 mo) and aged (22 mo) C57BL6/J mice treated with dasatinib and quercetin (D+Q) developed significant demyelination compared to vehicle-treated controls, though no cell death was observed in the brain. In vitro, oligodendrocyte progenitor cells treated with D+Q in differentiation media exhibited significantly reduced myelin basic protein protein and morphological complexity, also without inducing cell death. Bulk RNA sequencing and ingenuity pathway analysis of D+Q treated oligodendrocytes identified differentially expressed genes associated with endoplasmic reticulum stress. These data suggest that D+Q evokes the unfolded protein response in oligodendrocytes, causing oligodendrocyte dysfunction and myelination failure. Due to the resemblance between oligodendrocytes treated with D+Q and those found in MS lesions, D+Q treatment offers a potential method to model an aspect of oligodendrocyte dysfunction relevant to MS. Therefore, understanding the mechanism by which D+Q perturb oligodendrocyte function may provide insight into some of the pathological features contributing to disease progression in MS.
- 17 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (12)
Open AccessSenolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum
Aging is a primary risk factor for disease progression in multiple sclerosis (MS). Because of this, treatments that can reduce the consequences of molecular aging, like senescence, have been proposed as a strategy to address disease progression. However, the effects of senolytics, a class of drugs which selectively ablate senescent cells, on the central nervous system are largely unknown. Here, we examined the effects of senolytic treatment on myelination and oligodendrocyte function in vivo using C57BL6/J mice and in vitro using primary rat oligodendrocyte cultures. Initial data showed that naïve young (3 to 4 mo) and aged (22 mo) C57BL6/J mice treated with dasatinib and quercetin (D+Q) developed significant demyelination compared to vehicle-treated controls, though no cell death was observed in the brain. In vitro, oligodendrocyte progenitor cells treated with D+Q in differentiation media exhibited significantly reduced myelin basic protein protein and morphological complexity, also without inducing cell death. Bulk RNA sequencing and ingenuity pathway analysis of D+Q treated oligodendrocytes identified differentially expressed genes associated with endoplasmic reticulum stress. These data suggest that D+Q evokes the unfolded protein response in oligodendrocytes, causing oligodendrocyte dysfunction and myelination failure. Due to the resemblance between oligodendrocytes treated with D+Q and those found in MS lesions, D+Q treatment offers a potential method to model an aspect of oligodendrocyte dysfunction relevant to MS. Therefore, understanding the mechanism by which D+Q perturb oligodendrocyte function may provide insight into some of the pathological features contributing to disease progression in MS.
- Open Access
- 13 October 2025
- Published by Springer Nature in Research Square
Adrenergic stress misdirects erythropoiesis compromising cancer immunity
Psychological stress is well known to cause weaker immunity. Stress, through the hypothalamus-pituitary-adrenal axis, induces secretion of cortisol, which causes immune suppression. Recently, stress-induced adrenergic mechanisms have begun to be shown to mediate immune suppression. Our work here reveals a novel axis whereby stress modulates erythropoiesis via the fight-or-flight hormones, and through it, immune suppression. Elevated levels of catecholamines, acting through 2-adrenergic receptors on precursor cells in erythroid differentiation, mis-direct erythroid differentiation causing accumulation of aberrant erythroid precursor cells (EPC) in mice as well as humans. EPC suppress priming as well as expansion of the CD8+ T cell response through their effect on dendritic cells (DC); EPC trogocytose cell surface MHC I from DC, and DC exposed to EPC are less effective at T cell activation. EPC suppress tumor immunity in several models and this suppression is exacerbated during adrenergic stress. The magnitude of suppression of tumor immunity by EPC is comparable to that mediated by regulatory T cells. Higher expression of CD71, a marker for EPC, is associated with poor overall and disease free survival in many human cancers. Our results uncover a role for adrenergic signaling in erythropoiesis, and establish erythroid cells, in addition to the lymphoid and myeloid cells, as significant determinants of cancer immunity.
- 13 October 2025
- Published by Springer Nature in Research Square
Open AccessAdrenergic stress misdirects erythropoiesis compromising cancer immunity
Psychological stress is well known to cause weaker immunity. Stress, through the hypothalamus-pituitary-adrenal axis, induces secretion of cortisol, which causes immune suppression. Recently, stress-induced adrenergic mechanisms have begun to be shown to mediate immune suppression. Our work here reveals a novel axis whereby stress modulates erythropoiesis via the fight-or-flight hormones, and through it, immune suppression. Elevated levels of catecholamines, acting through 2-adrenergic receptors on precursor cells in erythroid differentiation, mis-direct erythroid differentiation causing accumulation of aberrant erythroid precursor cells (EPC) in mice as well as humans. EPC suppress priming as well as expansion of the CD8+ T cell response through their effect on dendritic cells (DC); EPC trogocytose cell surface MHC I from DC, and DC exposed to EPC are less effective at T cell activation. EPC suppress tumor immunity in several models and this suppression is exacerbated during adrenergic stress. The magnitude of suppression of tumor immunity by EPC is comparable to that mediated by regulatory T cells. Higher expression of CD71, a marker for EPC, is associated with poor overall and disease free survival in many human cancers. Our results uncover a role for adrenergic signaling in erythropoiesis, and establish erythroid cells, in addition to the lymphoid and myeloid cells, as significant determinants of cancer immunity.
- 22 September 2025
- Published by Elsevier in Experimental Hematology
- Vol. 151, 105265
Building a transparent and functional laboratory culture: guidelines for creating a Laboratory Handbook for principal investigators
- 22 September 2025
- Published by Elsevier in Experimental Hematology
- Vol. 151, 105265
Building a transparent and functional laboratory culture: guidelines for creating a Laboratory Handbook for principal investigators
- 2 June 2023
- Published by Elsevier in Experimental Hematology
- Vol. 124, 36-44.e3
Assay optimization for the objective quantification of human multilineage colony-forming units
- 2 June 2023
- Published by Elsevier in Experimental Hematology
- Vol. 124, 36-44.e3
Assay optimization for the objective quantification of human multilineage colony-forming units
- Open Access
- 20 April 2022
- Published by Elsevier in Experimental Hematology
- Vol. 111, 66-78
Downregulation of SATB1 by miRNAs reduces megakaryocyte/erythroid progenitor expansion in preclinical models of Diamond–Blackfan anemia
- 20 April 2022
- Published by Elsevier in Experimental Hematology
- Vol. 111, 66-78
Open AccessDownregulation of SATB1 by miRNAs reduces megakaryocyte/erythroid progenitor expansion in preclinical models of Diamond–Blackfan anemia
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100543
MRTFA: A critical protein in normal and malignant hematopoiesis and beyond
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100543
Open AccessMRTFA: A critical protein in normal and malignant hematopoiesis and beyond
- 22 August 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (18) , 1547-1557
Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice
The mechanisms underlying thrombocytosis in patients with iron deficiency anemia remain unknown. Here, we present findings that support the hypothesis that low iron biases the commitment of Megakaryocytic-Erythroid Progenitors (MEP) toward the megakaryocytic (Mk) lineage in both human and mouse. In MEP of Transmembrane serine protease 6 knockout (Tmprss6-/-) mice, which exhibit iron deficiency anemia and thrombocytosis, we observed a Mk bias, decreased labile iron, and decreased proliferation relative to wild-type (WT) MEP. Bone marrow transplantation assays suggest that systemic iron deficiency, rather than a local role for Tmprss6-/-in hematopoietic cells, contributes to the MEP lineage commitment bias observed in Tmprss6-/-mice. Non-transgenic mice with acquired iron deficiency anemia also show thrombocytosis and Mk biased MEP. Gene expression analysis reveals that mRNAs encoding genes involved in metabolic, VEGF, and ERK pathways are enriched in Tmprss6-/-versus WT MEP. Corroborating our findings from the murine models of iron deficiency anemia, primary human MEP exhibit decreased proliferation and Mk-biased commitment after knockdown of Transferrin Receptor 2, a putative iron sensor. Signal transduction analyses reveal that both human and murine MEP have lower levels of phospho-ERK1/2 in iron deficient conditions compared to controls. These data are consistent with a model in which low iron in the marrow environment affects MEP metabolism, attenuates ERK signaling, slows proliferation, and biases MEP toward Mk lineage commitment. Key Points Low iron in the environment promotes megakaryocytic commitment of MEP. MEP from mice with iron deficiency anemia show decreased proliferation and decreased ERK phosphorylation.
- 22 August 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (18) , 1547-1557
Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice
The mechanisms underlying thrombocytosis in patients with iron deficiency anemia remain unknown. Here, we present findings that support the hypothesis that low iron biases the commitment of Megakaryocytic-Erythroid Progenitors (MEP) toward the megakaryocytic (Mk) lineage in both human and mouse. In MEP of Transmembrane serine protease 6 knockout (Tmprss6-/-) mice, which exhibit iron deficiency anemia and thrombocytosis, we observed a Mk bias, decreased labile iron, and decreased proliferation relative to wild-type (WT) MEP. Bone marrow transplantation assays suggest that systemic iron deficiency, rather than a local role for Tmprss6-/-in hematopoietic cells, contributes to the MEP lineage commitment bias observed in Tmprss6-/-mice. Non-transgenic mice with acquired iron deficiency anemia also show thrombocytosis and Mk biased MEP. Gene expression analysis reveals that mRNAs encoding genes involved in metabolic, VEGF, and ERK pathways are enriched in Tmprss6-/-versus WT MEP. Corroborating our findings from the murine models of iron deficiency anemia, primary human MEP exhibit decreased proliferation and Mk-biased commitment after knockdown of Transferrin Receptor 2, a putative iron sensor. Signal transduction analyses reveal that both human and murine MEP have lower levels of phospho-ERK1/2 in iron deficient conditions compared to controls. These data are consistent with a model in which low iron in the marrow environment affects MEP metabolism, attenuates ERK signaling, slows proliferation, and biases MEP toward Mk lineage commitment. Key Points Low iron in the environment promotes megakaryocytic commitment of MEP. MEP from mice with iron deficiency anemia show decreased proliferation and decreased ERK phosphorylation.
- 12 March 2019
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 119 (05) , 744-757
Epithelial (E)-Cadherin is a Novel Mediator of Platelet Aggregation and Clot Stability
Cadherins play a major role in mediating cell–cell adhesion, which shares many parallels with platelet–platelet interactions during aggregate formation and clot stabilization. Platelets express epithelial (E)-cadherin, but its contribution to platelet function and/or platelet production is currently unknown. To assess the role of E-cadherin in platelet production and function in vitro and in vivo, we utilized a megakaryocyte-specific E-cadherin knockout mouse model. Loss of E-cadherin in megakaryocytes does not affect megakaryocyte maturation, platelet number or size. However, platelet dysfunction in the absence of E-cadherin is revealed when conditional knockout mice are challenged with acute antibody-mediated platelet depletion. Unlike wild-type mice that recover fully, knockout mice die within 72 hours post-antibody administration, likely from haemorrhage. Furthermore, conditional knockout mice have prolonged tail bleeding times, unstable clot formation, reduced clot retraction and reduced fibrin deposition in in vivo injury models. Murine platelet aggregation in vitro in response to thrombin and thrombin receptor activating peptide is compromised in E-cadherin null platelets, while aggregation in response to adenosine diphosphate (ADP) is not significantly different. Consistent with this, in vitro aggregation of primary human platelets in response to thrombin is decreased by an inhibitory E-cadherin antibody. Integrin activation and granule secretion in response to ADP and thrombin are not affected in E-cadherin null platelets, but Akt and glycogen synthase kinase 3β (GSK3β) activation are attenuated, suggesting a that E-cadherin contributes to aggregation, clot stabilization and retraction that is mediated by phosphoinositide 3-kinase/Akt/GSK3β signalling. In summary, E-cadherin plays a salient role in platelet aggregation and clot stability. * These authors contributed equally to this work.
- 12 March 2019
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 119 (05) , 744-757
Epithelial (E)-Cadherin is a Novel Mediator of Platelet Aggregation and Clot Stability
Cadherins play a major role in mediating cell–cell adhesion, which shares many parallels with platelet–platelet interactions during aggregate formation and clot stabilization. Platelets express epithelial (E)-cadherin, but its contribution to platelet function and/or platelet production is currently unknown. To assess the role of E-cadherin in platelet production and function in vitro and in vivo, we utilized a megakaryocyte-specific E-cadherin knockout mouse model. Loss of E-cadherin in megakaryocytes does not affect megakaryocyte maturation, platelet number or size. However, platelet dysfunction in the absence of E-cadherin is revealed when conditional knockout mice are challenged with acute antibody-mediated platelet depletion. Unlike wild-type mice that recover fully, knockout mice die within 72 hours post-antibody administration, likely from haemorrhage. Furthermore, conditional knockout mice have prolonged tail bleeding times, unstable clot formation, reduced clot retraction and reduced fibrin deposition in in vivo injury models. Murine platelet aggregation in vitro in response to thrombin and thrombin receptor activating peptide is compromised in E-cadherin null platelets, while aggregation in response to adenosine diphosphate (ADP) is not significantly different. Consistent with this, in vitro aggregation of primary human platelets in response to thrombin is decreased by an inhibitory E-cadherin antibody. Integrin activation and granule secretion in response to ADP and thrombin are not affected in E-cadherin null platelets, but Akt and glycogen synthase kinase 3β (GSK3β) activation are attenuated, suggesting a that E-cadherin contributes to aggregation, clot stabilization and retraction that is mediated by phosphoinositide 3-kinase/Akt/GSK3β signalling. In summary, E-cadherin plays a salient role in platelet aggregation and clot stability. * These authors contributed equally to this work.